Nothing Special   »   [go: up one dir, main page]

Wang et al., 2018 - Google Patents

Discovery of hydrocarbon-stapled short α-helical peptides as promising Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors

Wang et al., 2018

View PDF
Document ID
2762351640173572258
Author
Wang C
Xia S
Zhang P
Zhang T
Wang W
Tian Y
Meng G
Jiang S
Liu K
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

The hexameric α-helical coiled-coil formed between the C-terminal and N-terminal heptad repeat (CHR and NHR) regions of class I viral fusion proteins plays an important role in mediating the fusion of the viral and cellular membranes and provides a clear starting point …
Continue reading at pubs.acs.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Similar Documents

Publication Publication Date Title
Wang et al. Discovery of hydrocarbon-stapled short α-helical peptides as promising Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors
Stephens et al. Inhibiting HIV fusion with a β-peptide foldamer
Cai et al. Development of peptide and small‐molecule HIV‐1 fusion inhibitors that target gp41
McGaughey et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb
Walensky et al. Hydrocarbon-stapled peptides: principles, practice, and progress: miniperspective
JP5653219B2 (en) Control of viral host membrane fusion by an artificial helix based on hydrogen-bonded surrogates
Wang et al. De novo design of α-helical lipopeptides targeting viral fusion proteins: a promising strategy for relatively broad-spectrum antiviral drug discovery
JP5788178B2 (en) Compositions and methods for the treatment of viral infections
Lu et al. Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41
Hilimire et al. HIV-1 frameshift RNA-targeted triazoles inhibit propagation of replication-competent and multi-drug-resistant HIV in human cells
Nomura et al. Cell-permeable stapled peptides based on HIV-1 integrase inhibitors derived from HIV-1 gene products
Shepherd et al. Modular α-helical mimetics with antiviral activity against respiratory syncitial virus
Bai et al. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket
Wang et al. Design, synthesis, and biological evaluation of highly potent small molecule–peptide conjugates as new HIV-1 fusion inhibitors
Meng et al. Design and biological evaluation of m-xylene Thioether-stapled short helical peptides targeting the HIV-1 gp41 Hexameric coiled–coil fusion complex
Wang et al. Supercoiling structure-based design of a trimeric coiled-coil peptide with high potency against HIV-1 and human β-coronavirus infection
Wang et al. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains
Xue et al. An HR2-mimicking sulfonyl-γ-AApeptide is a potent pan-coronavirus fusion inhibitor with strong blood–brain barrier permeability, long half-life, and promising oral bioavailability
Rashad et al. Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus–Cell Interface
Bailey et al. Disulfide sensitivity in the Env protein underlies lytic inactivation of HIV-1 by peptide triazole thiols
Kobayakawa et al. Hybrids of small-molecule CD4 mimics with polyethylene glycol units as HIV entry inhibitors
McGillick et al. Origins of resistance to the HIVgp41 viral entry inhibitor T20
Murugan et al. Peptide-based antiviral drugs
Herrera et al. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide
Chong et al. The N-Terminal T–T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity